1
|
Liu Z, Ren X, Yang Z, Mei L, Li W, Tu C, Li Z. Prognostic and clinical value of circPRKCI expression in diverse human cancers. Chin Med J (Engl) 2024; 137:152-161. [PMID: 37718264 PMCID: PMC10798697 DOI: 10.1097/cm9.0000000000002844] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2023] [Indexed: 09/19/2023] Open
Abstract
BACKGROUND Highly expressed in various human cancers, circular RNA Protein Kinase C Iota (circPRKCI) has been reported to play an important role in cancer development and progression. Herein, we sought to reveal the prognostic and clinical value of circPRKCI expression in diverse human cancers. METHODS We searched the Pubmed, Web of Science, and the Cochrane Library databases from inception until May 16, 2021. The relationship between circPRKCI expression and cancer patients' survival, including overall survival (OS) and disease-free survival (DFS), was assessed by pooled hazard ratios (HR) with corresponding 95% confidence interval (CI). The correlation between circPRKCI expression and clinical outcomes was evaluated using odds ratios (OR) with corresponding 95% CI. The data were analyzed by STATA software (version 12.0) or Review Manager (RevMan 5.3). RESULTS A total of 15 studies with 1109 patients were incorporated into our meta-analysis. The results demonstrated that high circPRKCI expression was significantly related to poor OS (HR = 1.96, 95% CI: 1.61, 2.39, P <0.001) when compared with low circPRKCI expression in diverse human cancers. However, elevated circPRKCI expression was not associated with DFS (HR = 1.34, 95% CI: 0.93, 1.95, P = 0.121). Furthermore, the patient with a higher circPRKCI expression was prone to have a larger tumor size, advanced clinical stage, and lymph node metastasis, but it was not significantly correlated with age, gender, and distant metastasis. CONCLUSION Elevated circPRKCI expression was correlated with worse OS and unfavorable clinical features, suggesting a novel prognostic and predictive role of circPRKCI in diverse human cancers.
Collapse
Affiliation(s)
- Zhongyue Liu
- Department of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China
- Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China
| | - Xiaolei Ren
- Department of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China
- Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China
| | - Zhimin Yang
- Department of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China
- Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China
| | - Lin Mei
- Department of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China
- Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China
| | - Wenyi Li
- Department of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China
- Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China
| | - Chao Tu
- Department of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China
- Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China
| | - Zhihong Li
- Department of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China
- Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China
| |
Collapse
|
2
|
Pan C, Ding Z, Dai J, Yang L, Wei Y, Wang X. CircSMARCA5
functions as a potential biomarker for clinicopathology and therapy in solid tumors: A systematic review and meta‐analysis. PRECISION MEDICAL SCIENCES 2023. [DOI: 10.1002/prm2.12100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/31/2023] Open
|
3
|
Foroumadi R, Rashedi S, Asgarian S, Mardani M, Keykhaei M, Farrokhpour H, Javanshir S, Sarallah R, Rezaei N. Circular RNA MYLK as a prognostic biomarker in patients with cancers: A systematic review and meta‐analysis. Cancer Rep (Hoboken) 2022; 5:e1653. [PMID: 35701309 PMCID: PMC9458501 DOI: 10.1002/cnr2.1653] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2021] [Revised: 05/14/2022] [Accepted: 05/19/2022] [Indexed: 11/08/2022] Open
Abstract
Background Aims Methods Results Conclusions
Collapse
Affiliation(s)
- Roham Foroumadi
- School of Medicine Tehran University of Medical Sciences Tehran Iran
- Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA) Universal Scientific Education and Research Network (USERN) Tehran Iran
- Non‐Communicable Diseases Research Center Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences Tehran Iran
| | - Sina Rashedi
- School of Medicine Tehran University of Medical Sciences Tehran Iran
- Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA) Universal Scientific Education and Research Network (USERN) Tehran Iran
- Non‐Communicable Diseases Research Center Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences Tehran Iran
| | - Sara Asgarian
- School of Medicine Iran University of Medical Sciences Tehran Iran
| | - Mahta Mardani
- School of Medicine Tehran University of Medical Sciences Tehran Iran
- Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA) Universal Scientific Education and Research Network (USERN) Tehran Iran
| | | | - Hossein Farrokhpour
- School of Medicine Tehran University of Medical Sciences Tehran Iran
- Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA) Universal Scientific Education and Research Network (USERN) Tehran Iran
- Non‐Communicable Diseases Research Center Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences Tehran Iran
| | - Salar Javanshir
- School of Medicine Tehran Medical Sciences Branch, Islamic Azad University Tehran Iran
| | - Rojin Sarallah
- School of Medicine Tehran Medical Sciences Branch, Islamic Azad University Tehran Iran
| | - Nima Rezaei
- Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA) Universal Scientific Education and Research Network (USERN) Tehran Iran
- Research Center for Immunodeficiencies Children's Medical Center, Tehran University of Medical Sciences Tehran Iran
- Department of Immunology School of Medicine, Tehran University of Medical Sciences Tehran Iran
| |
Collapse
|
4
|
Zhang X, Huang Y, Pang X. Value of serum p53, PKD1, and MAP2K4 in evaluating the condition and prognosis of endometrial carcinoma. Am J Transl Res 2022; 14:5059-5067. [PMID: 35958483 PMCID: PMC9360844] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2022] [Accepted: 06/08/2022] [Indexed: 06/15/2023]
Abstract
OBJECTIVE To analyze the p53, PKD1, and MAP2K4 expressions in serum of patients with endometrial carcinoma (EC) and their prognostic value. METHODS A total of 84 patients with EC who were treated in our hospital between January 2018 and January 2020 were enrolled into a research group. There were 50 healthy individuals over the same time who were included in a control group for a retrospective analysis. qRT-PCR was used for quantifying the relative levels of p53, PKD1, and MAP2K4 in the serum of the control group and the research groups (in both cancer and paracancerous tissues). The associations of p53, PKD1, and MAP2K4 with pathological features of EC were analyzed. Patients were followed up for 1 year to observe their death and analyze the associations of p53, PKD1, and MAP2K4 with prognosis of EC. RESULTS The patients with EC had low p53 and MAP2K4 levels and high PKD1 levels (P<0.05). The p53, MAP2K4, and PKD1 levels in serum were relevant to EC differentiation, FIGO stage, lymph node metastasis, and deep myometrial invasion (P<0.05). During the follow-up of prognosis, the serum levels of p53 and MAP2K4 in dead patients were lower than those in surviving patients. PKD1 in former patients was higher (P<0.05). CONCLUSION The low expressions of p53 and MAP2K4 and high expression of PKD1 in EC cases were related with disease progression. These expressions can help effectively evaluate the prognosis and survival of patients. They are of crucial research and reference significance for future diagnosis and therapy.
Collapse
Affiliation(s)
- Xiang Zhang
- Gynecology Department Ward2, Cangzhou Central Hospital Cangzhou 061000, Hebei Province, P. R. China
| | - Yue Huang
- Gynecology Department Ward2, Cangzhou Central Hospital Cangzhou 061000, Hebei Province, P. R. China
| | - Xuecheng Pang
- Gynecology Department Ward2, Cangzhou Central Hospital Cangzhou 061000, Hebei Province, P. R. China
| |
Collapse
|
5
|
Suo M, Lin Z, Guo D, Zhang A. Hsa_circ_0056686, derived from cancer-associated fibroblasts, promotes cell proliferation and suppresses apoptosis in uterine leiomyoma through inhibiting endoplasmic reticulum stress. PLoS One 2022; 17:e0266374. [PMID: 35390056 PMCID: PMC8989227 DOI: 10.1371/journal.pone.0266374] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2021] [Accepted: 03/19/2022] [Indexed: 12/12/2022] Open
Abstract
Abnormal expression of circular RNAs (circRNAs) in cancer-associated fibroblasts (CAFs) is involved in the tumor-promoting ability of CAFs. Hsa_ circ_ 0056686 has been reported to affect leiomyoma size. The purpose of this study is to investigate the regulatory role of hsa_circ_0056686 in CAFs on uterine leiomyoma (ULM). The primary CAFs and corresponding normal fibroblasts (NFs) were isolated from the tumor zones of ULM tissues and adjacent, respectively. Hsa_circ_0056686 level was higher in CAFs than NFs, and also higher in ULM tissues than in adjacent tissues. CAFs-CM significantly increased the proliferation and migration and inhibited apoptosis of ULM cells, as confirmed by CCK-8, transwell, and flow cytometry assays. Moreover, conditioned medium (CM) from CAFs transfected with hsa_circ_0056686 shRNA (CAFssh-circ_0056686-CM) abolished CAFs-mediated proliferation, migration and apoptosis of ULM cells. CAFs-CM suppressed the expression of endoplasmic reticulum stress (ERS) marker proteins and induced the expression of extracellular matrix (ECM) marker proteins, thus suppressing ERS and increasing ECM accumulation, which could be declined by CAFssh-circ_0056686-CM. Meanwhile, knockdown of hsa_circ_0056686 reversed the inhibitory effects of CAFs-CM on brefeldin A-induced cell apoptosis. Luciferase gene reporter and RNA pull-down assays indicated that miR-515-5p directly bound with hsa_circ_0056686. MiR-515-5p overexpression restored the hsa_circ_0056686-shRNA-mediated malignant biological behaviors of ULM cells. Hsa_circ_0056686 contributed to tumor-promoting effects of CAFs in ULM, manifested by promoting ULM cell proliferation and migration and reducing ERS-induced apoptosis through sponging miR-515-5p.
Collapse
Affiliation(s)
- Meifang Suo
- Department of Medical Laboratory, Zhumadian Central Hospital, Zhumadian, China
| | - Zhichen Lin
- Department of Burns, the 990th Hospital of the Joint Staff of the People’s Liberation Army, Zhumadian, China
| | - Dongfang Guo
- Department of Medical Laboratory, Zhumadian Central Hospital, Zhumadian, China
| | - Airong Zhang
- Department of Medical Laboratory, Zhumadian Central Hospital, Zhumadian, China
- * E-mail:
| |
Collapse
|
6
|
Chao F, Wang S, Zhang C, Han D, Xu G, Chen G. The Emerging Role of Circular RNAs in Prostate Cancer: A Systematic Review. Front Cell Dev Biol 2021; 9:681163. [PMID: 34386491 PMCID: PMC8353182 DOI: 10.3389/fcell.2021.681163] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2021] [Accepted: 07/06/2021] [Indexed: 11/13/2022] Open
Abstract
Prostate cancer is one of the most common malignant tumors that threaten the health of men. It is urgent to explore new molecular targets and develop new drugs for the treatment of prostate cancer. Circular RNAs (circRNAs) are aberrantly expressed in various malignant tumors. The dysregulated circRNAs are involved in the metastasis, tumor growth, drug resistance, and immunosuppression of malignant tumors. The present review systematically summarized publications concerning the biological implications of circRNAs in prostate cancer. The PubMed and Web of Science databases were used to retrieve publications concerning circRNAs and prostate cancer until June 16, 2021. The following keywords were used in the literature search: (circRNA OR circular RNA) AND prostate cancer. 73 publications were enrolled in the present systematic review to summarize the role of circRNAs in prostate cancer. The dysregulated and functional circRNAs were involved in the cell cycle, proliferation, migration, invasion, metastasis, drug resistance and radiosensitivity of prostate cancer. In addition, circRNAs could function through EVs and serve as prognostic and diagnostic biomarkers. Certain circRNAs were correlated with clinicopathological features of prostate cancer. A comprehensive review of the molecular mechanism of the tumorigenesis and progression of prostate cancer may contribute to the development of new therapies of prostate cancer in the future.
Collapse
Affiliation(s)
- Fan Chao
- Department of Urology, Jinshan Hospital, Fudan University, Shanghai, China
| | - Shiyu Wang
- Department of Urology, Jinshan Hospital, Fudan University, Shanghai, China
| | - Cong Zhang
- Department of Urology, Jinshan Hospital, Fudan University, Shanghai, China
| | - Dunsheng Han
- Department of Urology, Jinshan Hospital, Fudan University, Shanghai, China
| | - Guoxiong Xu
- Research Center for Clinical Medicine, Jinshan Hospital, Fudan University, Shanghai, China
| | - Gang Chen
- Department of Urology, Jinshan Hospital, Fudan University, Shanghai, China
| |
Collapse
|
7
|
Jangjou A, Meisami AH, Jamali K, Niakan MH, Abbasi M, Shafiee M, Salehi M, Hosseinzadeh A, Amani AM, Vaez A. The promising shadow of microbubble over medical sciences: from fighting wide scope of prevalence disease to cancer eradication. J Biomed Sci 2021; 28:49. [PMID: 34154581 PMCID: PMC8215828 DOI: 10.1186/s12929-021-00744-4] [Citation(s) in RCA: 24] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2021] [Accepted: 06/10/2021] [Indexed: 12/29/2022] Open
Abstract
Microbubbles are typically 0.5-10 μm in size. Their size tends to make it easier for medication delivery mechanisms to navigate the body by allowing them to be swallowed more easily. The gas included in the microbubble is surrounded by a membrane that may consist of biocompatible biopolymers, polymers, surfactants, proteins, lipids, or a combination thereof. One of the most effective implementation techniques for tiny bubbles is to apply them as a drug carrier that has the potential to activate ultrasound (US); this allows the drug to be released by US. Microbubbles are often designed to preserve and secure medicines or substances before they have reached a certain area of concern and, finally, US is used to disintegrate microbubbles, triggering site-specific leakage/release of biologically active drugs. They have excellent therapeutic potential in a wide range of common diseases. In this article, we discussed microbubbles and their advantageous medicinal uses in the treatment of certain prevalent disorders, including Parkinson's disease, Alzheimer's disease, cardiovascular disease, diabetic condition, renal defects, and finally, their use in the treatment of various forms of cancer as well as their incorporation with nanoparticles. Using microbubble technology as a novel carrier, the ability to prevent and eradicate prevalent diseases has strengthened the promise of effective care to improve patient well-being and life expectancy.
Collapse
Affiliation(s)
- Ali Jangjou
- Department of Emergency Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Amir Hossein Meisami
- Department of Emergency Medicine, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran
| | - Kazem Jamali
- Trauma Research Center, Shahid Rajaee (Emtiaz) Trauma Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Mohammad Hadi Niakan
- Trauma Research Center, Shahid Rajaee (Emtiaz) Trauma Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Milad Abbasi
- Department of Medical Nanotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Mostafa Shafiee
- Department of Medical Nanotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Majid Salehi
- Department of Tissue Engineering, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran
- Tissue Engineering and Stem Cells Research Center, Shahroud University of Medical Sciences, Shahroud, Iran
| | - Ahmad Hosseinzadeh
- Thoracic and Vascular Surgery Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Ali Mohammad Amani
- Department of Medical Nanotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Ahmad Vaez
- Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran
| |
Collapse
|